Type I Glanzmann's
thrombasthenia is a rare congenital platelet function disorder, characterized by undetectable
platelet membrane glycoprotein IIb-IIIa (GPIIb-IIIa). Severe
bleeding is controlled by transfusion of normal platelets, leading in some cases to the occurrence of anti-GPIIb-IIIa
isoantibodies, which induces a loss of transfused platelet efficacy. We used immunoadsorption on
protein A Sepharose (IA-PA), which has been shown to be efficient in decreasing the titre of
antibodies in several
immune diseases, in three patients with Glanzmann's
thrombasthenia and anti-GPIIb-IIIa
isoantibodies on five different occasions. IA-PA was well tolerated with no deleterious side-effects reported. It induced a dramatic decrease of total
immunoglobulin (Ig)G, including anti-GPIIb-IIIa isoantibody levels, as assessed by the
monoclonal antibody-specific immobilization of platelet
antigens test and the ex vivo inhibition of normal platelet aggregation induced by the patient's platelet-rich or platelet-poor plasma. Elimination of the antibody was associated with a correction of the bleeding time following
platelet transfusion. IA-PA combined with
platelet transfusion made it possible to control two life-threatening haemorrhages, and allowed two
surgical procedures and one
bone marrow transplantation to be performed safely. Our experience suggests that IA-PA, which restores the haemostatic efficacy of
platelet transfusion, is a valuable therapeutic strategy in patients with Glanzmann's
thrombasthenia and anti-GPIIb-IIIa
isoantibodies.